Arix Bioscience (LSE:ARIX) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ARIX Stoklara Genel Bakış

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity.

Şirket hakkında

ARIX temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	2/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Fiyat-Kazanç oranı ( 11.8 x) UK piyasasının ( 16.6 x) altındadır

Bu yıl karlı hale geldi

Risk Analizi

Kazançlar son 5 yılda yılda 16.4% oranında azaldı

Arix Bioscience plc Rakipler

Rights and Issues Investment Trust

LSE:RIII

UK£122.4m

TMT Investments

AIM:TMT

US$98.8m

EJF Investments

LSE:EJFI

UK£67.3m

City of London Investment Group

LSE:CLIG

UK£189.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Arix Bioscience
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£1.42
52 Haftanın En Yüksek Seviyesi	UK£1.45
52 Haftanın En Düşük Seviyesi	UK£0.97
Beta	1.05
11 Aylık Değişim	6.77%
3 Aylık Değişim	28.51%
1 Yıllık Değişim	22.41%
33 Yıllık Değişim	-31.73%
5 Yıllık Değişim	-12.88%
Halka arzdan bu yana değişim	-32.06%

Son Haberler & Güncellemeler

Recent updates

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Jan 13

Hissedar Getirileri

	ARIX	GB Capital Markets	GB Pazar
7D	-1.0%	-0.8%	0.1%
1Y	22.4%	28.9%	9.7%

Getiri vs. Endüstri: ARIX geçen yıl % 28.9 oranında getiri sağlayan UK Capital Markets sektörünü aştı.

Getiri vs Piyasa: ARIX geçen yıl % 9.7 oranında getiri sağlayan UK Piyasasını aştı.

Fiyat Oynaklığı

Is ARIX's price volatile compared to industry and market?
ARIX volatility
ARIX Average Weekly Movement	2.6%
Capital Markets Industry Average Movement	4.0%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: ARIX son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ARIX 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	9	n/a	arixbioscience.com

Arix Bioscience plc Temel Bilgiler Özeti

Arix Bioscience'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ARIX temel i̇stati̇sti̇kler
Piyasa değeri	UK£176.52m
Kazançlar(TTM)	UK£14.96m
Gelir(TTM)	UK£14.16m

11.8x

F/K Oranı

12.5x

P/S Oranı

ARIX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ARIX gelir tablosu (TTM)
Gelir	UK£14.16m
Gelir Maliyeti	UK£0
Brüt Kâr	UK£14.16m
Diğer Giderler	-UK£799.00k
Kazançlar	UK£14.96m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.12
Brüt Marj	100.00%
Net Kâr Marjı	105.64%
Borç/Özkaynak Oranı	0%

ARIX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ARIX Stoklara Genel Bakış

Ödüller

Risk Analizi

Arix Bioscience plc Rakipler

LSE:RIII

UK£122.4m

AIM:TMT

US$98.8m

LSE:EJFI

UK£67.3m

LSE:CLIG

UK£189.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Price target increased to UK£2.56

Less than half of directors are independent

Independent Non-Executive Chairman recently bought UK£78k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Price target increased to UK£2.56

Less than half of directors are independent

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Price target increased to UK£2.56

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

New 90-day high: UK£2.22

Executive Chairman recently bought UK£377k worth of stock

Investor sentiment improved over the past week

New 90-day high: UK£1.96

Market bids up stock over the past week

Analysts update estimates

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: UK£1.60

Price target raised to UK£1.71

New 90-day high: UK£1.12

New 90-day high - UK£0.97

Price target raised to UK£1.40

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Arix Bioscience plc Temel Bilgiler Özeti

11.8x

12.5x

Kazanç ve Gelir